RxDoctor Payments Data

Absalom Tilley, MD

Internal Medicine · Malvern, ARNPI 1275558918

Payments from drug & device makers

$1,701in general payments, 2019–2025

Across 71 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$385
  • Gilead$239
  • Grifols USA, LLC$134
  • AstraZeneca$131
  • AbbVie$125
  • Pfizer$90
  • plus $597 from 16 others

What the payments were for

  • Food & beverage$1,62596%
  • Education$764%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,701 in reported general payments places this provider in the 75th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$5,402
Medicare patients
165
Services billed
405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$60,029
FarxigaDapagliflozin Propanediol55$52,029
BiktarvyBictegrav/Emtricit/Tenofov Ala12$47,593
JanuviaSitagliptin Phosphate20$18,138
XareltoRivaroxaban21$13,824
Bydureon BciseExenatide Microspheres13$10,760
Combivent RespimatIpratropium/Albuterol Sulfate22$10,736
JardianceEmpagliflozin15$10,225
PremarinEstrogens, Conjugated28$7,295
SymbicortBudesonide/Formoterol Fumarate23$7,277
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen23$5,562
Chlorpromazine Hcl11$4,192
Levemir FlexpenInsulin Detemir16$3,952
DuleraMometasone/Formoterol11$3,888
Dexlansoprazole DrDexlansoprazole14$3,120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$90$67,32490 claims
AstraZenecaFarxiga, Symbicort$131$59,30678 claims
GileadBiktarvy$239$47,59312 claims
MerckJanuvia, Dulera$55$22,02631 claims
Johnson & JohnsonXarelto$55$13,82421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Malvern

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →